Letters sent to healthcare professionals in September 2017

Letters were sent in September about Dacogen (decitabine), Eperzan▼(albiglutide), ERWINASE, ReoPro (abciximab), and recombinant human erythropoietins.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 26 October 2017

• Therapeutic area: Cancer, Cardiovascular disease and lipidology, Endocrinology, diabetology and metabolism, Haematology, Paediatrics and neonatology and Urology and nephrology

In September 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

• Dacogen (decitabine) 50 mg, powder for concentrate for solution for infusion – change in the recommendations for diluting reconstituted Dacogen solution

• Eperzan▼(albiglutide): global discontinuation of medicine — do not initiate new patients; transition all current patients to an alternative therapy by July 2018

• ERWINASE from BATCH 184G* should be used with a 5-micron filter needle

• ReoPro (abciximab) 2 mg/mL solution for injection or infusion: supply shortage

• Recombinant human erythropoietins: risk of severe cutaneous adverse reactions

Article citation: Drug Safety Update volume 11, issue 3; October 2017: 5.

Published 26 October 2017